Misplaced Pages

Cyanovirin-N

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Cyanovirin) Protein
This article may require cleanup to meet Misplaced Pages's quality standards. The specific problem is: Spelling, Grammar, Style, Repeating & Unsourced Content. Please help improve this article if you can. (October 2017) (Learn how and when to remove this message)

Cyanovirin-N (CV-N) is a protein produced by the cyanobacterium Nostoc ellipsosporum that displays virucidal activity against several viruses, including human immunodeficiency virus (HIV). A cyanobacterial protein called cyanovirin-N (CV-N) has strong anti-human immunodeficiency virus (HIV) neutralizing properties. The virucidal activity of CV-N is mediated through specific high-affinity interactions with the viral surface envelope glycoproteins gp120 and gp41, as well as to high-mannose oligosaccharides found on the HIV envelope. In addition, CV-N is active against rhinoviruses, human parainfluenza virus, respiratory syncytial virus, and enteric viruses. The virucidal activity of CV-N against influenza virus is directed towards viral haemagglutinin.

The blue-green alga Nostoc ellipsosporum naturally contains the protein cyanovirin-N. The National Cancer Institute (NCI) in the United States carried out the initial isolation and characterisation of this protein in 1999. The use of cyanovirin-N as an antiviral drug, particularly against HIV, has since been the subject of investigation. Its ability to bind to the HIV-encapsulating glycoprotein gp120 has been demonstrated in several studies, which has led to the development of Cyanovirin-N-based therapies and preventatives.

Structure

Cyanovirin-N is a lengthy, mostly beta-sheet protein that displays internal two-fold pseudosymmetry. The fundamental atomic root-mean-square of the two sequence repeats (1-50 and 51-101) differs by 1.3 A while sharing 32% of the same sequence. The total fold depends on a number of interactions between the two repetitions, therefore they don't actually belong in separate domains. CV-N has a complex fold composed of a duplication of a tandem repeat of two homologous motifs comprising three-stranded beta-sheet and beta-hairpins.

References

  1. Zappe H, Snell ME, Bossard MJ (2008). "PEGylation of cyanovirin-N, an entry inhibitor of HIV". Adv. Drug Deliv. Rev. 60 (1): 79–87. doi:10.1016/j.addr.2007.05.016. PMID 17884238.
  2. Dey, Barna, Danica L. Lerner, Paolo Lusso, Michael R. Boyd, John H. Elder, and Edward A. Berger. “Multiple Antiviral Activities of Cyanovirin-N: Blocking of Human Immunodeficiency Virus Type 1 gp120 Interaction with CD4 and Coreceptor and Inhibition of Diverse Enveloped Viruses.” Journal of Virology 74, no. 10 (2000): 4562–69. https://doi.org/10.1128/jvi.74.10.4562-4569.2000.)
  3. Botos I, Wlodawer A (February 2003). "Cyanovirin-N: a sugar-binding antiviral protein with a new twist". Cell. Mol. Life Sci. 60 (2): 277–87. doi:10.1007/s000180300023. PMC 11138712. PMID 12678493. S2CID 10579615.
  4. O'Keefe BR, Smee DF, Turpin JA, Saucedo CJ, Gustafson KR, Mori T, Blakeslee D, Buckheit R, Boyd MR (August 2003). "Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin". Antimicrob. Agents Chemother. 47 (8): 2518–25. doi:10.1128/aac.47.8.2518-2525.2003. PMC 166092. PMID 12878514.
  5. ^ Boyd, MR; Gustafson, KR; McMahon, JB; Shoemaker, RH; O'Keefe, BR; et al. (June 1997). "Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development". Antimicrobial Agents and Chemotherapy. 41 (6): 1521–1530. doi:10.1128/AAC.41.7.1521. PMC 163952. PMID 9210678.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  6. Bewley, C.; Gustafson, K.; Boyd, M.; Covell, D.G.; Bax, A.; Clore, G.M.; Gronenborn, A.M. (1998). "Solution structure of cyanovirin-N, a potent HIV-inactivating protein". Nature Structural and Molecular Biology. 5 (7): 571–578. doi:10.1038/828. PMID 9665171. S2CID 11367037.
  7. Botos I, O'Keefe BR, Shenoy SR, Cartner LK, Ratner DM, Seeberger PH, Boyd MR, Wlodawer A (September 2002). "Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides". J. Biol. Chem. 277 (37): 34336–42. doi:10.1074/jbc.M205909200. PMID 12110688.

External links

Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Capsid inhibitors
Entry/fusion inhibitors
(Discovery and development)
Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))
Maturation inhibitors
Protease Inhibitors (PI)
(Discovery and development)
1 generation
2 generation
Reverse-transcriptase
inhibitors
(RTIs)
Nucleoside and
nucleotide (NRTI)
Non-nucleoside (NNRTI)
(Discovery and development)
1 generation
2 generation
Combined formulations
Pharmacokinetic boosters
Experimental agents
Uncoating inhibitors
Transcription inhibitors
Translation inhibitors
BNAbs
Other
Failed agents
°DHHS recommended initial regimen options. Formerly or rarely used agent.
Categories: